News stories about Anthera Pharmaceuticals (NASDAQ:ANTH) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern rates the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Anthera Pharmaceuticals earned a coverage optimism score of 0.18 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 46.2084618900957 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the news stories that may have impacted Accern Sentiment’s rankings:
- Anthera Pharmaceuticals Announces Appointment of Patrick Murphy … – GlobeNewswire (press release) (globenewswire.com)
- Anthera Pharmaceuticals Announces Appointment of Patrick Murphy as Senior Vice President, Manufacturing (finance.yahoo.com)
- Volatile Stock to Watch – Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH) – Alpha Beta Stock (alphabetastock.com)
- Anthera Pharmaceuticals, Inc. (ANTH) -Active Stock under Investors’ Interest – Wallstreet Investorplace (wallstreetinvestorplace.com)
- Anthera Pharmaceuticals, Inc. (ANTH) – Momentum Stock to Focus – Wall Street Morning (wallstreetmorning.com)
Anthera Pharmaceuticals (ANTH) traded up $0.05 during trading on Thursday, hitting $1.84. 305,700 shares of the stock were exchanged, compared to its average volume of 373,200. Anthera Pharmaceuticals has a one year low of $1.20 and a one year high of $6.24. The company has a market cap of $23.13, a P/E ratio of -0.34 and a beta of 2.71.
Anthera Pharmaceuticals (NASDAQ:ANTH) last released its quarterly earnings data on Monday, November 6th. The biopharmaceutical company reported ($0.58) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.90) by $0.32. During the same quarter last year, the firm posted ($4.85) earnings per share. sell-side analysts expect that Anthera Pharmaceuticals will post -3.09 earnings per share for the current fiscal year.
ANTH has been the topic of several recent research reports. Zacks Investment Research raised shares of Anthera Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.00 price target on the stock in a report on Tuesday, October 10th. HC Wainwright reaffirmed a “buy” rating and set a $3.00 price target on shares of Anthera Pharmaceuticals in a research report on Tuesday, September 19th. Finally, ValuEngine raised shares of Anthera Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Sunday.
ILLEGAL ACTIVITY WARNING: “Anthera Pharmaceuticals (ANTH) Getting Somewhat Positive Media Coverage, Report Finds” was originally reported by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this article on another site, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The legal version of this article can be read at https://transcriptdaily.com/2018/01/04/anthera-pharmaceuticals-anth-getting-somewhat-positive-media-coverage-report-finds.html.
Anthera Pharmaceuticals Company Profile
Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.
Receive News & Ratings for Anthera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.